이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

정상 노인과 알츠하이머병 위험에서 청반 기능 (LEAD)

2026년 11월 4일 업데이트: NYU Langone Health

Growing evidence suggests that Alzheimer's disease (AD) pathological changes begin decades before clinical symptoms and tau abnormalities in the locus coeruleus (LC) can be observed since midlife. We have previously demonstrated functional vulnerability of the LC to aging and stress, as well as an association between higher cerebrospinal fluid (CSF) tau and impaired sleep phenomena influenced by the LC. We now aim to test whether LC dysfunction can be measured in preclinical AD stages by LC targeted imaging, and whether it objectively affects sleep architecture and attention. We will test this hypothesis in 30 cognitively normal older adults by performing a full clinical evaluation, one night of polysomnography, a lumbar puncture to obtain cerebrospinal fluid, [11C]MRB PET-MR, and attention testing. This study has the potential to identify a new mechanism by which tau pathology contributes to sleep and attention dysfunction and may provide a new therapeutic target for AD prevention.

연구 개요

상세 설명

The purpose of this study is three-fold: to test whether lower NET availability in the LC is associated with: first, CSF tau levels typical of preclinical stages of AD (Aim 1); second, reduced REM and spindle density (Aim 2); and third, impaired performance on attention tasks (Aim 3). The goal is to test the overarching hypothesis that LC dysfunction occurs in preclinical AD stages, can be measured with MRB-PET, and translates into impairment of sleep architecture (LC tonic dysfunction) and attention (LC phasic dysfunction).

연구 유형

중재적

등록 (실제)

34

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • New York
      • New York, New York, 미국, 10029
        • Icahn School of Medicine Mount Sinai
      • New York, New York, 미국, 10016
        • NYU Grossman School of Medicine

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

55년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Male and female subjects with normal cognition and 55-75 years of age will be enrolled.
  • Subjects will be within normal limits on neurological and psychiatric examinations.
  • All subjects enrolled will have a CDR of 0. This will be evaluated through a clinical interview administered by a study physician (informant interview will not be required).
  • All subjects will have had a minimum of 12 years of education.

Exclusion Criteria:

  • History of brain tumor, MRI evidence of brain damage or brain disease including significant trauma, hydrocephalus, seizures, stroke, mental retardation or other serious neurological disorder (e.g. Parkinson's disease or other movement disorders).
  • Significant history of alcoholism or drug abuse.
  • Significant history of psychiatric illness (e.g., schizophrenia, bipolar, PTSD, or life-long history of major depression).
  • Geriatric Depression Scale (short form)>6.
  • Insulin dependent diabetes.
  • Evidence of clinically relevant cardiac, pulmonary, endocrine or hematological conditions.
  • Physical impairment of such severity as to adversely affect the validity of psychological testing.
  • Any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard for MRI imaging.
  • History of a first-degree family member with early onset (age <60 years) dementia.
  • Irregular sleep-wake rhythms (based on the actigraphy recordings) or significant OSA (AHI4%≥15).
  • Taking Coumadin/warfarin and/or medications affecting cognition or sleep.
  • Failure to complete all study visit within 4 months

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 기초 과학
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: 인지적으로 정상(CN) 노인

Nocturnal polysomnography (NPSG) to measure REM sleep and sleep spindles characteristics.

Lumbar puncture (LP) to measure CSF P-Tau, T-Tau and Aβ42/40 ratio.

PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-[11C]O-methylreboxetine ([11C]MRB) to measure NET availability.

Psychomotor vigilance task (PVT) and the OddBall to measure test taskattention performance.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Methylreboxetine (MRB)-LC Mean Standardized Uptake Value Ratio (SUVR) Values
기간: Visit 4 (1-4 weeks after LP that occurred on day 14)
Visit 4 (1-4 weeks after LP that occurred on day 14)
Total Rapid Eye Movement (REM) Duration (Min)
기간: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

REM sleep is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study.

Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of Time Spent in REM Sleep
기간: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

REM sleep is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study.

Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of REM Runs That Are Less Than 5 Minutes
기간: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of REM Runs That Are Greater Than or Equal to 5 Minutes
기간: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of REM Runs That Are Greater Than or Equal to 10 Minutes
기간: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of Correct Responses on the Picture Test
기간: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

The "Picture" test is used to measure the strength of the participants' memory by using a series of images. Before sleep, participants identify whether or not the image was inside or outside and whether or not the picture was emotional or neutral to them. After sleep, the participant will be shown images where some are new and some are old and asked whether or not they saw them before sleep. The images are selected from The International Affective Picture System.

Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Number of Sleep Spindles That Occur Per Minute During the N2 Stage of Sleep (N2 Spindle Density)
기간: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

N2 Spindle Density is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study.

Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Mean Psychomotor Vigilance Test (PVT) Reaction Time
기간: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

PVT measures the reaction speed to a randomly time-occuring visual stimuli, allowing the assessment of several aspects of attention including response times, attention lapses and false starts.

Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Picture Test Response Time
기간: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

The "Picture" test is used to measure the strength of the participants' memory by using a series of images. Before sleep, participants identify whether or not the image was inside or outside and whether or not the picture was emotional or neutral to them. After sleep, the participant will be shown images where some are new and some are old and asked whether or not they saw them before sleep. The images are selected from The International Affective Picture System.

Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

2차 결과 측정

결과 측정
측정값 설명
기간
Levels of Hyperphosphorylated Tau (P-Tau)
기간: Visit 4 (1-4 weeks after LP that occurred on day 14)

Levels will be derived from the plasma and reported in pg/mL

Visit 4 (1-4 weeks after LP that occurred on day 14)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Ricardo Osorio, NYU Langone Health

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2020년 8월 6일

기본 완료 (실제)

2024년 3월 26일

연구 완료 (실제)

2024년 3월 26일

연구 등록 날짜

최초 제출

2020년 5월 21일

QC 기준을 충족하는 최초 제출

2020년 5월 21일

처음 게시됨 (실제)

2020년 5월 27일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 6일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 4일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

All of the individual participant data collected during the trial, after deidentification.

IPD 공유 기간

Immediately following publication. No end date.

IPD 공유 액세스 기준

The investigator who proposed to use the ricardo.osorio@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다